Dompe Famaceutici S.p.A. to Acquire 100% of Anabasis, an Italian Biopharmaceutical Ophthalmology Company
2/28/2012 6:21:18 AM
MILAN--(BUSINESS WIRE)--Dompé, one of Italy’s leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.
Anabasis, founded in 1999 by a group of Italian scientists who were among the first to study the use of Nerve Growth Factor (NGF) – research which won Rita Levi-Montalcini the Nobel Prize – has advanced an ophthalmic formulation of NGF to preclinical and clinical stages for various diseases affecting both the anterior part of the eye, such as neurotrophic keratitis (NK) and dry eye, as well as the posterior part of the eye such as retinitis pigmentosa and glaucoma.
comments powered by